Table 5. Association of the CTI with dyslipidemia incidence across physical activity levels.
| Physical
activity |
Variable |
Number
of events, n |
Model
1 |
Model
2 |
Model
3 |
| HR |
95%
CI |
p |
HR |
95%
CI |
p |
HR |
95%
CI |
p |
| Light |
CTI
(per 1-unit) |
634 |
1.11 |
1.02-1.20 |
0.03 |
1.10 |
1.01-1.19 |
0.04 |
1.11 |
1.02-1.18 |
0.04 |
| Q1
(Ref) |
122 |
|
|
|
|
|
|
|
|
|
| Q2 |
141 |
1.03 |
0.87-1.22 |
0.72 |
1.02 |
0.86-1.21 |
0.76 |
1.03 |
0.85-1.22 |
0.77 |
| Q3 |
170 |
1.07 |
0.91-1.27 |
0.33 |
1.06 |
0.90-1.26 |
0.36 |
1.04 |
0.87-1.23 |
0.36 |
| Q4 |
201 |
1.25 |
1.05-1.49 |
0.02 |
1.23 |
1.04-1.47 |
0.03 |
1.21 |
1.02-1.44 |
0.03 |
| P
for trend |
|
|
|
0.02 |
|
|
0.03 |
|
|
0.03 |
| Moderate |
CTI
(per 1-unit) |
982 |
1.12 |
1.03-1.21 |
0.01 |
1.11 |
1.02-1.20 |
0.02 |
1.11 |
1.02-1.17 |
0.02 |
| Q1
(Ref) |
163 |
|
|
|
|
|
|
|
|
|
| Q2 |
218 |
1.01 |
0.86-1.18 |
0.90 |
1.01 |
0.86-1.18 |
0.91 |
1.01 |
0.84-1.17 |
0.93 |
| Q3 |
290 |
1.09 |
0.93-1.27 |
0.25 |
1.08 |
0.92-1.26 |
0.28 |
1.06 |
0.92-1.24 |
0.31 |
| Q4 |
311 |
1.28 |
1.09-1.50 |
0.01 |
1.26 |
1.07-1.49 |
0.01 |
1.24 |
1.05-1.46 |
0.02 |
| P
for trend |
|
|
|
0.01 |
|
|
0.02 |
|
|
0.02 |
| Vigorous |
CTI
(per 1-unit) |
395 |
1.30 |
1.08-1.56 |
0.01 |
1.29 |
1.07-1.55 |
0.01 |
1.26 |
1.05-1.53 |
0.02 |
| Q1
(Ref) |
95 |
|
|
|
|
|
|
|
|
|
| Q2 |
89 |
1.18 |
0.84-1.65 |
0.33 |
1.16 |
0.83-1.62 |
0.35 |
1.14 |
0.81-1.62 |
0.34 |
| Q3 |
82 |
1.25 |
0.90-1.74 |
0.15 |
1.23 |
0.88-1.72 |
0.18 |
1.21 |
0.86-1.72 |
0.20 |
| Q4 |
129 |
1.49 |
1.11-2.01 |
0.01 |
1.47 |
1.09-1.98 |
0.02 |
1.44 |
1.07-1.94 |
0.02 |
| P
for trend |
|
|
|
0.01 |
|
|
0.02 |
|
|
0.02 |
HR = hazard ratio; CI = confidence interval. Q1 denotes the lowest quartile, which served as the reference category. Model 1 included no covariate adjustment; Model 2 was adjusted for demographic and lifestyle characteristics (sex, age, residence, marital status, education, smoking, and alcohol consumption); and Model 3 additionally accounted for comorbid conditions such as chronic diseases, arthritis, liver disease, asthma, kidney disease, and gastrointestinal disorders, as well as the use of anti-diabetic medication, anti-hypertensive medication, and lipid-lowering medication as covariates. The p for trend was estimated by modeling the median value of each quartile as a continuous variable in the Cox regression model. Statistical significance was defined as a two-sided p < 0.05.
